Diamyd Medical
Presence
Diamyd Medical is a company listed under the stock ticker DMN (SE).
Executives
View the org chart displaying its 14 main executives
Most searched biographies at Diamyd Medical
Popular executive movements at Diamyd Medical
- Anders Essen-Möller, who was Board Member, is promoted to Chairman of the Board (posted on October 2 2023).
Create your alert
to follow the executive moves at Diamyd Medical.
Biotechnology
Diamyd Medical has 2,281 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Diamyd Medical
- Recruitment milestone reached in Diamyd® Phase 3 trial
- Diamyd Medical's main Shareholders announce their subscription commitments in the ongoing rights issue
- Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes
- Publication in Diabetologia highlights AI's potential for Type 1 Diabetes screening
- The Board of Directors in Diamyd Medical have resolved on a rights issue of approximately SEK 114 million
- Diamyd Medical to present new genetic data at the ASIT summit in Boston, MA
- Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®
- Quarterly Report I 23/24
- In-depth analysis of Diamyd® Phase II trial further supports value of preserved insulin secretion
- Diamyd Medical gains market research findings to guide U.S. commercial strategy
- View more press releases Close
Social media about Diamyd Medical
- Diamyd Medical on Wikipedia, Google News & Yahoo Finance
- Diamyd Medical on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Ulf Hannelius 
Call Diamyd Medical at +46 ...
